Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.
The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder.
Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.
In association with:
Video discussion of new technology that enables evidence-based decisions
Make better decisions that balance time, cost and risk across your portfolio